Tarsus Pharmaceuticals, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This filing reports annual results; standalone fourth-quarter financial results are not clearly provided in the supplied text. Tarsus is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue.
Business context and pipeline
The company’s lead candidate, TP-03 (lotilaner ophthalmic solution, 0.25%), is being developed for Demodex blepharitis. The FDA accepted its NDA in November 2022 and set a PDUFA decision date of August 25, 2023. The company also reported positive topline results from the pivotal Saturn-2 trial: 56% achieved collarette cure versus 13% on vehicle, and 52% achieved mite eradication versus 15% on vehicle; both comparisons had p<0.0001. TP-03 was generally well tolerated in the trial.
Other programs include TP-03 for meibomian gland disease (MGD), TP-04 for rosacea, and TP-05 for potential Lyme disease prophylaxis. Tarsus began the MGD Phase 2a Ersa trial in 2022; TP-05 Phase 1 Callisto results were positive and the Phase 2a Carpo trial began in December 2022. The company initiated the TP-04 Phase 2a Galatea trial in March 2023. These candidates remain investigational.
Financial and operating results
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Total revenue | $25.8 million | $57.0 million | Down $31.2 million |
| Research and development expense | $42.6 million | $41.7 million | Up $0.9 million |
| General and administrative expense | $44.9 million | $25.4 million | Up $19.6 million |
| Operating loss | $62.7 million | $12.2 million | Loss increased $50.6 million |
| Net loss | $62.1 million | $13.8 million | Loss increased $48.3 million |
| Net loss per share, basic and diluted | $2.52 | $0.67 | — |
| Net cash used in operating activities | $49.0 million | Net cash provided: $3.7 million | — |
Revenue consisted of China out-license license fees and collaboration revenue, not product sales. License fees were $23.9 million in 2022 versus $53.1 million in 2021; collaboration revenue was $1.9 million versus $4.0 million. The year-over-year revenue decrease reflects lower out-license-related amounts recognized. The filing provides no clear reported gross-margin figure; operating expenses substantially exceeded revenue.
Higher G&A reflected increased staffing and commercial preparation: personnel-related costs rose $10.4 million and commercial and market-research costs rose $9.7 million. R&D costs were broadly stable, with increased staffing and NDA-related spending largely offset by lower clinical costs following completion of Saturn-2. Stock-based compensation was $13.5 million, up from $8.5 million.
Liquidity, debt and cash flow
- At December 31, 2022, cash and cash equivalents were $71.7 million and marketable securities were $145.4 million, totaling $217.0 million. Current assets were $225.4 million and current liabilities were $15.4 million.
- Total liabilities were $35.0 million. Term loan carrying value, net of issuance costs and adjustments, was $19.4 million against $20.0 million principal outstanding. The facility is secured by substantially all assets, with a negative pledge on intellectual property.
- Operating cash outflow was $49.0 million. Investing cash outflow was $144.6 million, primarily purchases of marketable securities; financing cash inflow was $94.0 million, principally $74.4 million net proceeds from the May 2022 follow-on offering and a $20.0 million loan draw.
- Management estimated existing resources, expected China out-license milestone receipts and anticipated credit-facility draws would fund planned operations into at least the second half of 2026. This is an estimate dependent on assumptions, not a guarantee; management also said current resources would not support both TP-03 commercialization and continued development of other candidates without additional capital.
Material changes, outlook and risks
- Net loss widened substantially as revenue from the China out-license declined and G&A rose with commercial-launch preparation. Tarsus completed a $79.5 million gross follow-on equity offering in 2022, increasing shares outstanding and diluting existing holders.
- The company planned a potential U.S. TP-03 launch in the second half of 2023, contingent on FDA approval, and expected meaningful commercial-team expansion during 2023. It reported no product-revenue guidance or formal financial forecast.
- Through year-end 2022, Tarsus had received $80.0 million from LianBio, including upfront and milestone payments. Further consideration is contingent on development, regulatory and sales milestones, plus potential royalties; these amounts are not assured.
- After year-end, the credit facility was amended, and Tarsus drew an additional $5.0 million on March 15, 2023. The filing also discusses SVB’s March 2023 closure and transfer of its obligations to Silicon Valley Bridge Bank, while noting uncertainty about access to future facility availability.
- Key risks include FDA approval and launch uncertainty for TP-03; market uptake, diagnosis, coverage and reimbursement; continuing losses and potential need for more financing; clinical-development uncertainty for pipeline candidates; reliance on Elanco-licensed intellectual property and third-party manufacturers; and debt covenants and debt-service obligations. Market-size estimates are company estimates and may be overstated.
- No material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the independent auditor did not opine on internal-control effectiveness.
Important facts for investors to verify
- FDA’s decision and any labeling, manufacturing, or post-approval requirements for TP-03, as well as actual timing and cost of a potential launch.
- Whether launch execution, physician adoption, payer coverage, pricing and reimbursement support the company’s market assumptions.
- Quarterly cash burn, commercial spending, remaining cash runway, and the availability and terms of undrawn credit-facility tranches.
- Progress and final results from the Ersa, Carpo and Galatea trials, and the additional evidence regulators may require.
- Timing and likelihood of LianBio milestone and royalty receipts, and obligations owed to Elanco under the license agreements.
- Manufacturing readiness and supply-chain resilience, given reliance on third parties and limited qualified suppliers.